Immunoglobulin G monoclonal antibodies to Cryptococcus neoformans protect mice deficient in complement component C3

被引:70
作者
Shapiro, S
Beenhouwer, DO
Feldmesser, M
Taborda, C
Carroll, MC
Casadevall, A
Scharff, MD
机构
[1] Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10461 USA
[2] Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA
[3] Albert Einstein Coll Med, Dept Immunol & Microbiol, Bronx, NY 10461 USA
[4] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA
[5] Harvard Univ, Sch Med, Ctr Blood Res, Boston, MA 02115 USA
关键词
D O I
10.1128/IAI.70.5.2598-2604.2002
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Passive administration of monoclonal antibodies (MAbs) to the capsular polysaccharide of Cryptococcus neoformans can alter the course of infection in mice. In a murine model of cryptococcal infection, immunoglobulin G1 (IgG1), IgG2a, and IgG2b switch variants of the anti-capsular 3E5 MAb prolong the survival of lethally infected mice, whereas the 3E5 IgG3 MAb does not protect and in some cases enhances infection, shortening the life spans of infected mice. We examined the role of complement component C3 in Ab-mediated protection by determining the efficacy of the four mouse IgG subclasses against C. neoformans in mice genetically deficient in factor C3 as well as mice acutely depleted of C3. Similar to other complement-deficient animal models, C3(-/-) mice and mice depleted of C3 by cobra venom factor were more susceptible to C. neoformans infection than control mice, providing further evidence that complement is important in the host defense against the fungus. In the absence of C3, all IgG isotypes prolonged the lives of mice infected with C. neoformans, indicating that protection by IgG does not require the complement pathways. Furthermore, we observed protection with IgG3 in the complement-deficient mice, suggesting that complement is involved in the lack of protection observed with IgG3 in other mouse models.
引用
收藏
页码:2598 / 2604
页数:7
相关论文
共 61 条
[1]   Both Th1 and Th2 cytokines affect the ability of monoclonal antibodies to protect mice against Cryptococcus neoformans [J].
Beenhouwer, DO ;
Shapiro, S ;
Feldmesser, M ;
Casadevall, A ;
Scharff, MD .
INFECTION AND IMMUNITY, 2001, 69 (10) :6445-6455
[2]   Characterization of a murine monoclonal antibody to Cryptococcus neoformans polysaccharide that is a candidate for human therapeutic studies [J].
Casadevall, A ;
Cleare, W ;
Feldmesser, M ;
Glatman-Freedman, A ;
Goldman, DL ;
Kozel, TR ;
Lendvai, N ;
Mukherjee, J ;
Pirofski, LA ;
Rivera, J ;
Rosas, AL ;
Scharff, MD ;
Valadon, P ;
Westin, K ;
Zhong, ZJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (06) :1437-1446
[3]   ANTIBODIES ELICITED BY A CRYPTOCOCCUS-NEOFORMANS TETANUS TOXOID CONJUGATE VACCINE HAVE THE SAME SPECIFICITY AS THOSE ELICITED IN INFECTION [J].
CASADEVALL, A ;
MUKHERJEE, J ;
DEVI, SJN ;
SCHNEERSON, R ;
ROBBINS, JB ;
SCHARFF, MD .
JOURNAL OF INFECTIOUS DISEASES, 1992, 165 (06) :1086-1093
[4]   CR3-dependent phagocytosis by murine macrophages: Different cytokines regulate ingestion of a defined CR3 ligand and complement-opsonized Cryptococcus neoformans [J].
Cross, CE ;
Collins, HL ;
Bancroft, GJ .
IMMUNOLOGY, 1997, 91 (02) :289-296
[5]   ESTIMATION OF THE PREVALENCE OF CRYPTOCOCCAL INFECTION AMONG PATIENTS INFECTED WITH THE HUMAN-IMMUNODEFICIENCY-VIRUS IN NEW-YORK-CITY [J].
CURRIE, BP ;
CASADEVALL, A .
CLINICAL INFECTIOUS DISEASES, 1994, 19 (06) :1029-1033
[6]   A NEW FC RECEPTOR ON MOUSE MACROPHAGES BINDING IGG [J].
DIAMOND, B ;
YELTON, DE .
JOURNAL OF EXPERIMENTAL MEDICINE, 1981, 153 (03) :514-519
[7]  
DIAMOND RD, 1973, P SOC EXP BIOL MED, V144, P312, DOI 10.3181/00379727-144-37580
[8]  
DIAMOND RD, 1974, J IMMUNOL, V112, P2260
[9]  
Dodds A.W., 1997, COMPLEMENT PRACTICAL
[10]   INTRAVASCULAR CRYPTOCOCCAL CULTURE FILTRATE (CNEF) AND ITS MAJOR COMPONENT, GLUCURONOXYLOMANNAN, ARE POTENT INHIBITORS OF LEUKOCYTE ACCUMULATION [J].
DONG, ZM ;
MURPHY, JW .
INFECTION AND IMMUNITY, 1995, 63 (03) :770-778